Introduced in the U.S. House of Representatives on March 24, 2022, the Equitable Community Access to Pharmacist Services Act, H.R. 7213, would authorize pharmacists to provide care and receive reimbursement for pandemic-related services for our nation’s seniors.
We’re excited to announce the launch of the new APhA Learning Library! This new platform will make it easier than ever for you to get the education you need. Read about some key highlights of our new system.
APhA is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that result in improved workplaces, well-being, and ability to meet ethical obligations to patient safety.
APhA Institute on Substance Use Disorders in Salt Lake City, UT
Tools and resources to support your practice
An APhA member-only resource for pharmacists, pharmacy residents, student pharmacists, pharmacy technicians, and interprofessional health care team members involved in providing transitions of care (TOC) services.
This resource provides the latest information about how to bill for COVID-19 vaccines, including how to bill for additional doses and booster doses.
An outline of the key steps to implementing monoclonal antibody therapy administration services in community settings.
View CEO Blog
We hear you! Your pharmacy workplace is stressed and stretched. You have rapidly growing concerns for patient safety. Still, you are there—every day—to care for your patients despite conditions that seem to be working against you.
View all press releases
WASHINGTON, DC—The American Pharmacists Association (APhA) is deeply saddened by the horrific mass shootings that occurred over the weekend in Buffalo, NY and Laguna, CA.
View all news
CDC recently approved new pneumococcal vaccine (PCV) recommendations. Now, CDC recommends the use of either 20-valent pneumococcal conjugate vaccine (PCV20) alone or 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65 years or older and for adults aged 19 to 64 years with certain underlying medical conditions or other risk factors who have not previously received a PCV vaccine or whose previous vaccination history is unknown.
PCSK9 inhibitors appear to lower nonfatal myocardial infarction in adults with high or very high cardiovascular risk but not in those with low or moderate risk, according to a new study published in The BMJ.